Redeye endorses Ortoma’s received CE certification for OTS Hip Guide in accordance with MDR.
Redeye makes some revisions based on the Q4 report.
Redeye provides a short comment on Ortoma’s Q4 report this morning.
Redeye comments on Ortoma’s announcement yesterday that they have submitted a supplemental 510(k) to the FDA regarding the Custom OTS™ Hip.
Redeye comments on the announcement that the current CEO has left.
Redeye makes some revisions based on the Q3 report.
Redeye provides a short comment on Ortoma’s Q3 report this morning.
Redeye comments on the published order of SEK 31m for OTS™ Hip stemming from the distribution agreement signed with DePuy in September last ...
Redeye makes minor revisions based on the Q2 report.
Redeye provides a short comment on Ortoma’s Q2 report this morning.
Redeye makes minor revisions based on the Q1 report.
Redeye provides a short comment on Ortoma’s Q1 report this morning.
Redeye is pleased that Ortoma has received the 510(K) approval from the US FDA regarding the OTS™ Hip.
Redeye makes minor revisions based on the Q4 report.
Redeye provides a short comment on this morning’s Q4 report from Ortoma.
Redeye comments on the outcome of the TO 2B announcement published today.
Redeye is encouraged by the news that Ortoma continues to be active in the Japanese market and leverage the existing agreement with Johnson ...
Redeye is positively surprised that Ortoma has already received the first milestone payment from DePuy.
Redeye makes minor revisions based on the Q3 report.
Redeye provides a short comment on this morning’s Q3 report from Ortoma.
Redeye ups its near-term sales estimates for Ortoma following its USD8.
Redeye comments on Ortoma’s agreement with DePuy Synthes.
Redeye leaves its comments on Ortoma following its Q2 2023 report.
Redeye initiates coverage of Ortoma, a Swedish medtech company in early stage commercialisation with its Ortoma Treatment Solution (OTS™), h...
